PUBLICAÇÕES científicas

Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control

Herrero-Sánchez MC (1,2,3), Rodríguez-Serrano C (1,2,3), Almeida J (2,4), San-Segundo L (2,3), Inogés S [ES] (5), Santos-Briz Á (2,6), García-Briñón J (2,7), SanMiguel JF (8), Del Cañizo C (1,2,3), Blanco B (1,2).
(1) Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.
(2) Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
(3) Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain.
(4) Servicio de Citometría, Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain.
(5) Laboratorio de Inmunoterapia, Clínica Universidad de Navarra, Pamplona, Spain.
(6) Departamento de Patología, Hospital Universitario de Salamanca, Salamanca, Spain.
(7) Departamento de Biología Celular y Patología, Facultad de Medicina, Salamanca, Spain.
(8) Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain. 

Revisão:British Journal of Haematology

Data: 23/Fev/2016

Hematologia e Hemoterapia Imunologia e Imunoterapia [ES]

RESUMO

The mechanistic target of rapamycin (mTOR) pathway is crucial for the activation and function of T cells, which play an essential role in the development of graft-versus-host disease (GvHD).

Despite its partial ability to block mTOR pathway, the mTORC1 inhibitor rapamycin has shown encouraging results in the control of GvHD. Therefore, we considered that simultaneous targeting of both mTORC1 and mTORC2 complexes could exert a more potent inhibition of T cell activation and, thus, could have utility in GvHD control.

To assess this assumption, we have used the dual mTORC1/mTORC2 inhibitors CC214-1 and CC214-2. In vitro studies confirmed the superior ability of CC214-1 versus rapamycin to block mTORC1 and mTORC2 activity and to reduce T cell proliferation. Both drugs induced a similar decrease in Th1/Th2 cytokine secretion, but CC214-1 was more efficient in inhibiting naïve T cell activation and the expression of T-cell activation markers.

In addition, CC214-1 induced specific tolerance against alloantigens, while preserving anti-cytomegalovirus response. Finally, in a mouse model of GvHD, the administration of CC214-2 significantly improved mice survival and decreased GvHD-induced damages. In conclusion, the current study shows, for the first time, the immunosuppressive ability of CC214-1 on T lymphocytes and illustrates the role of CC214-2 in the allogeneic transplantation setting as a possible GvHD prophylaxis agent.

CITAÇÃO DO ARTIGO  Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13984.

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra